advertisement
Sugiyama K 9
Showing records 1 to 9 | Display all abstracts from Sugiyama K92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Araie M
Advances in Therapy 2021; 38: 1757-1775
92450 Glaucoma-related central visual field deterioration after vitrectomy for epiretinal membrane: topographic characteristics and risk factors
Tsuchiya S
Eye 2021; 35: 919-928
92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Sugiyama K
Advances in Therapy 2021; 38: 1757-1775
92450 Glaucoma-related central visual field deterioration after vitrectomy for epiretinal membrane: topographic characteristics and risk factors
Higashide T
Eye 2021; 35: 919-928
92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Aso K
Advances in Therapy 2021; 38: 1757-1775
92450 Glaucoma-related central visual field deterioration after vitrectomy for epiretinal membrane: topographic characteristics and risk factors
Udagawa S
Eye 2021; 35: 919-928
92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Kanemoto K
Advances in Therapy 2021; 38: 1757-1775
92450 Glaucoma-related central visual field deterioration after vitrectomy for epiretinal membrane: topographic characteristics and risk factors
Sugiyama K
Eye 2021; 35: 919-928
92099 Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
Kothapalli K; Kopczynski C; Senchyna M; Hollander DA
Advances in Therapy 2021; 38: 1757-1775
